ReproGo is developing **VasIntel**, an AI-powered platform that simulates how real human tissues respond to genes, compounds, and disease triggers --- enabling scientists and pharmaceutical companies to reduce lab burden, de-risk decisions, and accelerate discovery. Unlike traditional approaches that rely on animal testing or generic models, VasIntel is trained on **functional data from lab-grown human mini-organs** exposed to diabetic, inflammatory, and metabolic conditions. The platform integrates **functional, molecular, and metabolic responses**, making it uniquely suited to model complex diseases at the tissue level. Researchers can use VasIntel as a **virtual simulation tool** --- selecting disease pathways, running predictions, and comparing outcomes before moving to the lab. Future features will include **personalised modelling** based on small blood samples, allowing patient-specific simulations. The platform's initial focus is on diabetes-related vascular disease, where existing models often fail to predict real human outcomes. Long-term, VasIntel will expand to other areas including **cardiovascular, kidney, neurovascular, and rare inflammatory diseases**. This Innovate UK-funded feasibility study will explore VasIntel's **commercial and regulatory potential** through structured stakeholder engagement, pricing validation, and technical scoping. It builds on ReproGo's success delivering validated human tissue models and engagement with over 400 stakeholders during the Pioneer Group's AI in Health Accelerator --- where **98.1% of users said they would use the platform**. By supporting earlier, more accurate predictions and reducing reliance on animal tests, VasIntel offers a **human-relevant, sustainable alternative** for drug discovery. It aligns with the UK's mission to lead in ethical biomedical innovation and strengthens national capabilities in AI-powered life sciences.

Since their advent in 2006, induced pluripotent stem cells (iPSCs) have demonstrated a huge potential for disease modelling, drug discovery and regenerative medicine. Through genetic modification, adult cells already differentiated to specific tissues are reverted back, or 'reprogrammed' to an embryonic-like state, creating cells with self-renewal properties and the potential to be directed towards any cell type in the body. Human iPSCs can be derived from blood, and not only circumvent ethical issues presented by human embryonic stem cells (ESCs), but also enable the easy production of [patient-specific][0] [pluripotent stem cells][1] for individualised therapy. From patient blood, researchers can now generate iPSC-derived cardiac, neural and retinal cells among others, opening up a whole new avenue in the discovery and development of personalised medicine. Current process used to derive and programme iPSCs are slow, complex and expensive. The ReproGO technology allows human iPSCs to be generated rapidly by an automated system needing only a small volume of patient blood. By allowing a cost-effective, simple and reproducible production of patient iPSCs, ReproGO will accelerate the discovery and development of new therapies for multiple diseases. [0]: https://www.sciencedirect.com/topics/engineering/patient-specific "Learn more about Patient Specific from ScienceDirect's AI-generated Topic Pages" [1]: https://www.sciencedirect.com/topics/engineering/pluripotent-stem-cells "Learn more about Pluripotent Stem Cells from ScienceDirect's AI-generated Topic Pages"